Launch of Direct-to-Consumer Heart Wellness Check-Up Program in Bangkok, Thailand
Mango Wellness Co., Ltd. and My-Cardia Thailand Co., Ltd. to begin new remote cardiac monitoring service through pharmacies and clinics in the greater Bangkok market.
ESCONDIDO, CA / ACCESSWIRE / September 28, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) (“CBSC” or the “Company”), a provider of remote ECG cardiac monitoring products and services (myCam™ monitor and my-Cardia™ cloud-based software portal), both domestically and internationally, today announces the official launch of the “Heart Wellness Check-Up” program in Bangkok, Thailand through their authorized distributor Mango Wellness and My-Cardia Thailand. This new B2C remote program is being offered to consumers in partnership with 26 participating pharmacies and medical clinics in the greater Bangkok area. Using CBSC’s proprietary myCam™ remote cardiac event monitor and its unique features will help customers deal with heart-related issues and their well-being while dealing with Covid 19 and the quarantine requirements in Thailand. The “Heart Wellness Check-Up” program offers a hassle-free 10-day monitoring period that is delivered directly to the consumers’ home, remotely, without the need to make multiple trips to hospitals or clinics for evaluation or screening. ECG heart rhythm episodes can be transmitted directly to the my-Cardia™ propriety cloud-based software portal, anywhere, and at any time using the my-Cardia smartphone app on the customer’s iOS or Android phone or tablet through a cellular or Wi-Fi connection.
Several Tier 1 private and public hospitals have teamed up with Mango Wellness and My-Cardia Thailand on this new direct-to-consumer wellness program. They include Banpakok9, Ramkhamhaeng, Petcharavej, Vibhavadi, and Phyathai Nawamin, all major hospital centers in the greater Bangkok district. In addition, the Central Chest Institute of Thailand, a Tier 1 Government hospital, participates in the program. Cardiologists from these facilities will review and interpret any significant irregular ECG heart rhythm event and consult directly with Mango Wellness and My-Cardia Thailand customers, offering them a choice of either a direct appointment at the hospitals or one through a telemedicine video call option. Mango Wellness has already started an aggressive digital marketing campaign to promote awareness and the benefits of the “Heart Wellness Check-Up” program.
Charles Martin, CBSC CEO, stated, “the current pandemic and quarantine has forced our distributors to create a new path for patients to engage their physicians and hospitals in dealing with cardiac issues while they stay at home. The program offered by Mango Wellness and My-Cardia Thailand now places CBSC’s remote cardiac event monitor services into the direct-to-consumer market in Bangkok, Thailand. This alternative approach, together with the upcoming re-start of Mango Wellness and My-Cardia Thailand’s B2B hospital model after the lockdowns from the current pandemic have ended, will go a long way towards helping this distributor establish a solid foundation in both the Remote Cardiac Monitoring and Direct-to-Consumer markets in Thailand. CBSC also looks forward to the upcoming launch of cardiac service models in Malaysia, Singapore, and hopefully toward regulatory certification approval in mainland China.”
CB Scientific Inc. – Company Contact Information:
340 State Place
Escondido, CA 92029
Mango Wellness Co., Ltd. / My-Cardia Thailand Co., Ltd. Company Contact Information:
Mango Wellness Co., Ltd.
My-Cardia Thailand Co., Ltd.
190 Sutthisan Road, Intersection 1, Suite A2
Bangkok, Thailand 10400
+66 (0) 21015576 – Mango Wellness
+66 (0) 971566481 – My-Cardia Thailand
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.